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Summary In 20 patients with cisplatin-associated anaemia (haemoglobin less than 90 g -'), recombinant
human erythropoietin was administered subcutaneously three times a week on an outpatient basis. The initial
dose was 50 Units Kg- of body weight. If response was not achieved within 3 weeks, dose was increased to 75
Units Kg-'. Using the same criteria further excalation to 100 Units Kg-' was performed. If there was no
response erythropoietin was terminated. Fifteen patients obtained an increase in haemoglobin to above
100 g-' which was considered as a clinical response in this study, with a dose of 50 Units Kg-'; one patient
needed an erythropoietin dose of 75 Units Kg-' and one a dose of 100 Units Kg-'. Only three patients
required haemotransfusions and were considered non responders. Haemoglobin increases occurred despite
continuation of cisplatin chemotherapy. In conclusion subcutaneous low dose of erythropoietin seems to be
effective and safe in the treatment of cisplatin-induced anaemia.
Patients with cancer who receive chemotherapy frequently
develop anaemia (Gale, 1985). It can significantly contribute
to their morbidity and they often require haemotransfusions.
Cisplatin (CDDP) treatment is one of the most common
cause of chemotherapy-induced anaemia. In about 40% of
patients in fact anaemia develops during the treatment and
most of them require packed RBC transfusions (Rossof et
al., 1972; Von Hoff et al., 1979). The anaemia associated with
CDDP therapy is a normochromic, normocytic, hypop-
roliferative anaemia with a low reticulocyte count, similar to
that seen in patients with chronic renal failure (Rossof et al.,
1972; Eschbach et al., 1989). Although the etiology of this
anaemia is probably multifactorial, some studies showed that
in this anaemia the increase linear relationship between the
concentrations of haemoglobin and those of circulating
erythropoietin, that is observed in the other anaemic states
(iron deficiency; acute blood loss and hemolysis), was not
present in the same way of the anaemia of chronic renal
failure (Alexopoulos et al., 1986; Miller et al., 1990; Platanias
et al., 1991).
In the animal models of CDDP-associated anaemia, the
treatment with exogenous recombinant erythropoietin has
resulted in reversal of the anaemia (Matsumoto et al., 1990).
Recently a phase I-II study about treatment of CDDP-
induced anaemia with erythropoietin administered intra-
venously confirmed that erythropoietin is effective and well
tolerated in this condition (Miller et al., 1992).
We report the results of a pilot study of subcutaneous
erythropoietin in the treatment of CDDP-induced
anaemia.
Patients and methods
Patients
Twenty cancer patients, 11 men and nine women, median age
52 years (range 45-71), who were being treated with
chemotherapeutic regimen containing cisplatin, were entered
the study. Patients with following criteria were included in
the study: haemoglobin levels greater than 110 g-' prior the
chemotherapy; haemoglobin levels less than 90 gI` during
the treatment with CDDP; no severe symptoms or signs
related to anaemia that required haemotransfusions; no
previous chemotherapy; no previous radiation therapy to the
pelvic, thoracic or lumbar region; anaemia normochromic,
normocytic, with a low reticulocyte count; no concomitant
haemorrhage or haemolysis; no red blood cells transfusions
in the 4 weeks prior to the current chemotherapy regimen;
adequate bone marrow, renal, liver and cardiovascular func-
tions prior to chemotherapy.
Patients receiving androgen, antiandrogen or progestative
therapy were excluded.
Cisplatin chemotherapy was continued during the study.
Informed consent was obtained from all study subjects and
the study was approved by the ethical Committee of our
Hospital.
Treatment regimen
Erythropoietin (rHuEPO) used in this study was provided by
Cilag Italia, Milano. It was administered subcutaneously
every Monday, Wednesday and Friday, between 8 and
10 a.m. on an outpatient basis. The initial dose of rHuEPO
was 50 Units per Kilogram of body weight. If response was
not achieved within 3 weeks, dose was increased to 75 Units
per Kilogram. Using the same criteria further excalation to
100 Units per Kilogram was performed. If there was no
response rHuEPO was terminated. Oral iron supplements
were commenced if one of the following events occurred: (1)
serum iron <50 gdl-'; (2) transferrin saturation <20%; (3)
serum ferritin <10 ngmlh-'.
Clinical and laboratoring monitoring
Physical examinations were performed, vital signs were
recorded and samples were obtained for serum chemistries,
serum ferritin, folate levels, haematology assessment and
urinalysis, at baseline, every week and 4 weeks later the last
administration of rHuEPO. Chest X-rays and electrocardio-
grams were obtained at baseline and at the end of the
treatment.
Response criteria
A response was defined as an increase in haemoglobin con-
centrations to above 100 g 1I after 3 weeks of therapy with-
out transfusion. This level of haemoglobin was chosen
because patients with this degree of anaemia generally have a
good quality of life and do not need red cell transfusion. If
red cell transfusion became necessary at any time after the
start of therapy, the attempt of treatment was considered a
failure and rHuEPO therapy was discontinued.
Evaluation of toxic effects
Evaluation of toxic effects, focused on hypertension or
headache or other neurologic symptoms, which have been
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linked to rHuEPO treatment in patients with end-stage renal
disease or chronic renal failure were noted at weekly physical
examination for all the duration of treatment and 4 weeks
later the last administration of rHuEPO. Any signs or symp-
toms of local irritation at the the injection site, abnormal
vital signs, clinically significant abnormal laboratoristic
findings were recorded for consideration as toxic effects or
adverse reaction.
Results
Twenty patients entered the study. All were evaluable for
response and toxicity. Patients characteristics are summarised
in Table I.
Toxic effects
Treatment was well tolerated. No patient was removed from
the study because of rHuEPO related toxicity. Two patients
presented facial flushing and headache. None ofpatients had
hypertension, seizures or thrombohaemorragic complica-
tions.
Efficacy
Table II shows haemoglobin levels on day 1 and after three
weeks of rHuEPO therapy.
Fifteen patients obtained an increase in haemoglobin to
above 100gl-', which was considered as a clinical response
in this study, with a dose of 50 UKg-' and one required a
dose of 100 UKg-'. Only three patients required haemot-
ransfusions and were considered non responders (Table
II).
These haemoglobin increases occurred despite continuation
of CDDP chemotherapy.
Discussion
About 40% of patients develop anaemia during the
chemotherapy with cisplatin containing regimens. It can be a
dominant factor in symptoms and morbidity and most of
patients can require red blood cell transfusions (Von Hoff et
al., 1979; Rossof et al., 1972).
Although the mechanism ofCDDP-induced anaemia is not
well known, it appears that inadequate erythropoietin res-
ponse is important in the developing of this anaemia. In the
same way of chronic renal failure associated anaemia
(Eschbach et al., 1989) in CDDP-induced anaemia the linear
relation between the concentrations of haemoglobin and
those of circulating erythropoietin is not present and, despite
anaemia, low levels of erythropoietin in plasma have been
shown (Miller et al., 1990; Platanias et al., 1991; Matsumoto
et al., 1990; Miller et al., 1992; Rothmann et al., 1985). This
inadequate response was thought to be due to cisplatin-
associated nephrotoxicity (Platanias et al., 1991). However in
the study of Miller (1992) and in our study, renal function
appeared to be normal during cisplatin treatment, although
subclinical nephrotoxicity could not be excluded. Moreover
the erythropoietin response to anaemia was similar in the
patients receiving chemotherapy whether or not the treatment
included cisplatin (Platanias et al., 1991). This suggests that
chemotherapy may have an effect on the erythropoietin res-
ponse to anaemia that is independent of therapy-induced
nephrotoxicity.
Treatment with exogenous rHuEPO has resulted in rever-
sal of the anaemia in the animal models of CDDP-associated
anaemia (Matsumoto et al., 1990).
Recently Miller (1992) showed the efficacy of intravenous
erythropoietin in the treatment of CDDP-induced anaemia.
Twelve out of 21 patients obtained an increase of haemog-
lobin levels with a mild toxicity.
In our study we chose a subcutaneous route of rHuEPO
administration because it was shown to be effective and safe
Table I Patient characteristics on day 1 of
Characteristics
Sex
Male
Female
Age
Median
Range
Cancer
Stomach
Breast
Ovary
Melanoma
Head and neck
Chemotherapeutic regimens
CDDP (60mgm-2) q 2 weeks
CDDP (40 mg m-2)
+ weekly
SFU (500 mg m2)
CDDP (60mgm-2)
+ q 3 weeks
VP16 (100 mgm-2)
Dose of CDDP (mgm-2)
Median
Range
Haemoglobin-level g l'
Median
Range
White blood cells count x 07 1-'
Median
Range
Platelet count x 1071-'
Median
Range
Ferritin level ngml-'
Median
Range
study
No
11
9
52
45-71
10
3
3
1
3
8
9
3
240
180-320
86
75-89
4.8
4.1 -5.4
350
150-430
236
28-390
Erythropoietin levels mUl'
Median 148
Range 38-200
CDDP = cisplatin; 5FU = 5fluorouracil; VP16 = etoposide.
Table II Hemoglobin levels (g- 1) on day 1 and after 3 weeks of
rHuEPO (Ukg 1) therapy
No. rHuEPO Day I of After Change RBC
patients dose therapy therapy g 1-' transfusions
1 50 88 101 13 -
2 50 83 101 18 -
3 50 82 102 20 -
4 50 85 81 -4 2U
5 50 89 104 15 -
6 50 88 107 19 -
7 50 89 103 14 -
8 50 85 75 -10 -
75 75 73 -2 2U
9 50 85 109 24 -
10 50 85 83 -2 -
75 83 85 2 -
100 85 80 -5 2U
11 50 86 104 18 -
12 50 75 112 37 -
13 50 86 102 16 -
14 50 89 87 -2 -
75 87 102 15 -
15 50 88 88 - -
75 88 87 -1 -
100 87 103 16 -
16 50 86 104 18 -
17 50 88 107 19 -
18 50 89 124 35 -
19 50 88 113 25 -
20 50 89 109 20 -
RBC =red blood cell; rHuEPO= recombinant human
erythropoietin.158 S. CASCINU et al.
in the treatment of anaemia associated with chronic renal
failure, myeloma and other haematological diseases, and for
convenience because it can be administered on an outpatient
basis (Eschbach et al., 1989; Ludwig et al., 1990; Cazzola et
al., 1992). Furthermore rHuEPO subcutaneous injections
result in slow release from subcutaneous depots, providing
lower but more sustained plasma levels than intravenous
injections. In fact the pharmacokinetics of intravenously
administered rHuEPO are characterised by brief peaks in
plasma levels due to the relatively small distribution volume,
about the same as the plasma volume, and the short half-life
of about 6 to 8 h (McMahon et al., 1990; Erslev, 1991). For
these reasons subcutaneous administration can be advan-
tageous because even lower doses may be sufficient for a
certain erythropoietic effect.
The low dose was chosen on the basis of data reported
above and of preclinical findings that showed low doses
rHuEPO were sufficient for recovering from CDDP-induced
anaemia, whereas higher doses were required for the treat-
ment of 5-fluorouracil induced anaemia or other cytotoxic
drugs (Matsumoto et al., 1990).
In our study we obtained the remission of anaemia in 17
out of 20 patients with mild side effects. In 15 patients a dose
of 50 UKg-' three times a week was sufficient to maintain
haemoglobin levels higher than 100 g-'. In one patient a
dose of 75 UKg-I and in one patient a dose of 100 UKg-I
needed, while three patients were considered non responders
and required haemotransfusions.
Moreover it is of interest that our results seem to confirm
data obtained by Miller (1992) on the lack of prediction of
pretreatment erythropoietin levels to exogenous rHuEPO in
patients with CDDP anaemia. In fact in our study two out of
the three non responder patients presented the lowest levels
of pretreatment serum erythropoietin. These data are consis-
tent also with the reports by Ludwig (1990) and Oster (1990).
The findings of the present study show the effectiveness and
the safety of subcutaneous administration of rHuEPO even
with a lower dose respect to that demonstrated effective by
intravenous route. In fact while in Miller's study (1992) doses
of 100 UKg-' and 200 UKg-' five times weekly offered the
potentiation for optimal clinical response, in our study doses
of 50-75 UKg'- three times a week were sufficient to obtain
a clinical response.
For this reasons subcutaneous rHuEPO could be more
convenient than intravenous administration, also considering
the economic aspect. Considering that in our study 75 U
Kg-' three times a week could be the optimal dose whereas
in Miller's study the erythropoietin dose should be at least
100 U Kg-' five times a week, one week treatment requires
the use of 225 UKg-Iin our regimen and 500 UKg-' in
Miller's regimen for each patient. Because in Italy the price
of 1,000 U of rHuEPO is about $14 for hospital pharmacies
intravenous regimen is surely more expensive.
On the basis of these data further trials seem to be recom-
mended to define the optimal dose and route of administra-
tion in view of determining, by randomised studies, the real
effect on transfusion requirements and chemotherapy
administration.
References
ALEXOUPOLOS, C.G., CHALEVELAKIS, G., KATSOULIS, C. & PAL-
LIKARIS, G. (1986). Adverse effect of cis- diamminedichlorop-
latinum II (CDDP) on porphyrin metabolism in man. Cancer
Chemother. Pharmacol., 17, 165-170.
CAZZOLA, M., PONCHIO, L., BEGUIN, Y., ROSTI, V., BERGAMAS-
CHI, G., LIBERATO, N.L., FREGONI, V., NALLA, G., BAROSI, G. &
ASCARI, E. (1992). Subcutaneous erythropoietin for treatment of
refractory anemia in hematologic disorders. Results of a phase
I/II clinical trial. Blood, 79, 29-37.
ERSLEV, A.J. (1991). Erythropoietin N. Engl. J. Med., 324,
1339-1344.
ESCHBACH, J.W., KELLY, M.R., HALEY, N.R., ABELS, R.I. & ADAM-
SON, J.W. (1989). Treatment of the anemia of progressive renal
failure with recombinant human erythropoietin. N. Engl. J. Med.,
321, 158-163.
GALE, R.P. (1985). Antineoplastic chemotherapy myelosuppression:
mechanism and new approaches. Exp. Hematol., 13, (suppl. 16),
3-7.
LUDWIG, H., FRITZ, E., KOTZMAN, H., HOCKER, P., GISSLINGER,
H. & BARNAS, U. (1990). Erythropoietin treatment of anemia
associated with multiple myeloma. N. Engl. J. Med., 32,
1693-1699.
MATSUMOTO, T., ENDOH, K., KAMISANGO, K., AKAMATSU, K.,
KOIZUMI, K., HIGUCHI, M., IMAI, N., MITSUI, H. &
KAWAGUCHI, T. (1990). Effect of recombinant human eryth-
ropoietin on anticancer drug-induced anaemia. Br. J. Haematol.,
75, 463-468.
McMAHON, F.G., VARGAS, R., RYAN, M., JAIN, A.K., ABELS, R.I.,
PERRY, B. & SMITH, I.L. (1990). Pharmacokinetics and effects of
recombinant human erythropoietin after intravenous and sub-
cutaneous injection in healthy volunteers. Blood, 76,
1718-1722.
MILLER, C.B., JONES, R.J., PIANTADOSI, S., ABELOFF, M.D. &
SPIVAK, J.L. (1990). Decreased erythropoietin response in
patients with the anemia of cancer. N. Engl. J. Med., 322,
1689-1692.
MILLER, C.B., PLATANIAS, L.C., MILLS, S.R., ZAHURAK, M.L.,
RATAIN, M.J., ETTINGER, D.S. & JONES, R.J. (1992). Phase I-II
trial of erythropoietin in the treatment of cisplatin-associated
anemia. J. Natl Cancer Inst., 84, 98-103.
OSTER, W., HERRMANN, F., GAMM, H., ZEILE, H., LINDEMANN, A.,
MULLER, G., BRUNE, T., KRAEMER, H.P. & MERTELSMANN, R.
(1990). Erythropoietin for the treatment of anemia of malignancy
associated with neoplastic bone marrow infiltration. J. Clin.
Oncol., 8, 956-962.
PLATANIAS, L.C., MILLER, C.B., MICK, R., HART, R.D., OZER, H.,
MCEVILLY, J.M., JONES, R.J. & RATAIN, M.J. (1991). Treatment
ofchemotherapy-induced anemia with recombinant human eryth-
ropoietin in cancer patients. J. Clin. Oncol., 9, 2021-2026.
ROSSOF, A.H., SLAYTON, R.E. & PERLIA, C.P. (1972). Preliminary
clinical experience with cis-diamminedichloroplatinum(II) (NSC
119875, CACP). Cancer, 30, 1451-1456.
ROTHMANN, S.A., PAUL, P., WEICK, J.K., MCINTYRE, W.R. &
FANTELLI, F. (1985). Effect of cisdiamminedichloroplatinum on
erytropoietin production and hematopoietic progenitor cells. Int.
J. Cell Cloning, 3, 415-423.
VON HOFF, D.D., SCHILSKY, R., REICHERT, C.M., REDDICK, R.L.,
ROZENCWEIG, M., YOUNG, R.C. & MUGGIA, F.M. (1979). Toxic
effects of cisdichlorodiammineplatinum(II) in man. Cancer Treat.
Rep., 63, 1527-1531.